Search Bar & Filters
Found 116 Actively Recruiting clinical trials
Actively Recruiting
Researchers are conducting an open-label, multi-site, multi-cohort phase 12 trial to evaluate ODM-212 combined with other anti-cancer therapies in adults with advanced solid tumors such as mesothelioma, pancreatic cancer, and advanced non-small cell lung cancer NSCLC. The study aims to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and effectiveness of these combinations. The trial is divided into two parts dose escalation and dose expansionoptimization. Participants receive ODM-212 tablets alongside specified anti-cancer therapies depending on their cancer type. These include ipilimumab and nivolumab for mesothelioma, gemcitabine with nab-paclitaxel for pancreatic cancer, and sotorasib for NSCLC with a KRAS G12C mutation. Each drug has specific dosing schedules, such as intravenous infusions every 3 to 6 weeks or daily oral dosing in 21-day cycles. Participants will be monitored throughout the study for dose-limiting toxicities and adverse events over an average of 2 years. They will record daily adherence to oral medications and undergo evaluations including tumor biopsies and response assessments. The study involves regular visits for treatment administration and safety monitoring, with eligibility requiring good performance status and the ability to take oral medication.
Actively Recruiting
Researchers are investigating new treatment options for people with certain advanced or metastatic solid tumors that have alterations in the KRAS gene. This Phase 1 trial aims to evaluate the safety and tolerability of the drug MK-4716 when taken alone or in combination with other treatments. The study focuses on understanding possible side effects and how well participants tolerate these therapies. Participants will receive MK-4716 either by itself at different dose levels and schedules, or in combination with Pembrolizumab or Cetuximab, both given by intravenous infusion. The study has multiple groups running in parallel, each receiving one of these treatment approaches. MK-4716 is taken orally, and the combinations involve intravenous administration of the other drugs. During the trial, participants will be closely monitored for any dose-limiting toxicities and adverse events up to approximately 4 years. Researchers will assess drug levels in the blood at set timepoints to understand how MK-4716 behaves in the body. Participants will undergo regular evaluations including safety checks and measuring disease status. The study duration may extend over several years to gather long-term safety and response information.
Actively Recruiting
Researchers are evaluating tulisokibart as a treatment for radiographic axial spondyloarthritis r-axSpA, a type of arthritis causing pain, stiffness, and inflammation in the spine and pelvis joints. This condition leads to damage visible on X-rays. The study aims to find out if different doses of tulisokibart improve symptoms better than a placebo, which looks like the medicine but contains no active drug. Participants will be assigned to one of four groups a high dose, medium dose, low dose of tulisokibart, or a placebo. After 16 weeks, those on the low dose or placebo will be randomly reassigned to receive either the medium or high dose. The study includes a 16-week placebo-controlled period followed by a 124-week long-term extension, which consists of a 40-week main extension and an 84-week optional extension. Tulisokibart is given through subcutaneous injections. During the study, participants will undergo assessments of their arthritis symptoms using various scales and imaging, including MRI scans of the spine and pelvis. Researchers will monitor changes in pain, function, disease activity, and fatigue at baseline and after 16 weeks. Safety will be tracked throughout the study and for up to about 154 weeks. The study is scheduled to complete in early 2030.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and effectiveness of GX-03 topical ointment in adults with moderate to severe atopic dermatitis eczema. This Phase 2, adaptive, randomized, double-blind, vehicle-controlled study includes two stages Stage 1 completed with 50 participants to assess treatment responses and biomarkers, and Stage 2 currently enrolling approximately 135 participants with varying severity levels and significant itch symptoms. Participants are randomly assigned to receive either the GX-03 ointment or a matching vehicle ointment, applied at least twice daily to affected skin areas for 8 consecutive weeks. Stage 2 enrollment is stratified by baseline severity of eczema and itch level. The study uses an 8-week treatment period with assessments at Week 4 and Week 8 to measure improvement based on several eczema severity scales. During the study, participants attend visits at Week 4 and Week 8 for evaluation of skin condition using specific scores like vIGA-AD and EASI. Safety is monitored through tracking adverse events and local skin reactions. Participants must apply the study ointment daily and comply with study procedures during the 8-week period. The main outcomes focus on skin clearance and reduction in eczema severity at Weeks 4 and 8.
Actively Recruiting
Researchers are evaluating VVD-130037, a Kelch-like ECH Associated Protein 1 KEAP1 activator, in adults with advanced solid tumors in a first-in-human study. The study aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and early anti-tumor activity of VVD-130037, both alone and combined with other cancer treatments. This is an open-label, phase 1 trial sponsored by Vividion Therapeutics, Inc., focusing on patients whose cancer has progressed despite prior standard therapies. Participants receive escalating doses of VVD-130037 orally once or twice daily in 21- or 28-day treatment cycles. In Part 1 dose escalation, VVD-130037 is tested alone and combined with intravenous docetaxel, paclitaxel, or pembrolizumab at established schedules. Part 2 dose expansion administers VVD-130037 at the recommended dose for expansion RDE, alone or in combination, to further evaluate safety and activity. Treatment cycles vary by combination, with docetaxel given every 3 weeks and paclitaxel given on days 1, 8, and 15 of each cycle. Participants undergo regular assessments including monitoring for dose-limiting toxicities during the first treatment cycle and tracking adverse events over up to 4 years. Laboratory tests, electrocardiograms, and imaging evaluations measure drug concentrations, heart rhythm, and tumor response. Researchers also evaluate overall response rates, duration of response, progression-free survival, and disease control rates. Safety follow-up and detailed pharmacokinetic studies are part of the long-term observation to understand the effects of VVD-130037 and its combinations.
Actively Recruiting
Researchers are evaluating VVD-159642, a new drug that inhibits the RAS-PI3K pathway, in participants with advanced solid tumors. This first-in-human FIH Phase 11b study aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor effects of VVD-159642 alone and combined with sotorasib or trametinib. The trial focuses on patients whose tumors have specific genetic alterations or overexpress certain proteins related to cancer growth. Participants will receive VVD-159642 orally once daily in 21-day treatment cycles. The study has two parts Part 1 involves dose escalation of VVD-159642 alone to find the recommended dose. Part 2 uses this dose to further assess VVD-159642 alone or combined with sotorasib or trametinib after safety evaluations. The combinations are also given orally daily in 21-day cycles. During the study, participants undergo regular monitoring for side effects, vital signs, and lab tests up to about 29 months. Researchers measure dose-limiting toxicities, adverse events, and drug levels in the blood. Tumor response and disease progression are assessed by imaging following RECIST criteria. This long-term follow-up helps understand the drugs safety and activity in advanced solid tumor patients.
Actively Recruiting
Researchers are evaluating IBI343 in people with locally advanced unresectable or metastatic solid tumors in a Phase IaIb, multicenter, open-label, first-in-human study. The trial aims to assess the safety, tolerability, how the drug moves through the body, and its effectiveness. The study includes participants from China, Australia, and the US and involves various stages to find the best dose and combination therapies. IBI343 is given intravenously and the study is divided into multiple parts. Phase Ia includes dose escalation, dose expansion, and dose optimization for monotherapy, with doses adjusted to balance benefits and risks. Phase Ib includes combination therapy with chemotherapy drugs like FOLFIRINOX or mFOLFOX, given every two to three weeks, with randomized groups to determine the optimal dose and safety. Participants will have regular visits for treatment and monitoring, including physical exams, laboratory tests, and imaging to measure tumor response using RECIST criteria. Safety is closely followed through adverse event tracking up to two years, along with assessments of drug levels in the body and immune response. The study also evaluates how tumor markers relate to treatment response, with total participation lasting up to two years.
Actively Recruiting
Researchers are evaluating the efficacy and safety of rilvegostomig compared to pembrolizumab, both combined with platinum-based doublet chemotherapy, as a first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC whose tumors express PD-L1 at 1% or higher. This Phase III, randomized, double-blind, global study focuses on patients without certain genetic mutations who have advanced disease not suitable for curative treatment. The trial aims to provide new treatment options for this patient group by comparing two immunotherapy approaches combined with chemotherapy. Participants receive either rilvegostomig or pembrolizumab, each given intravenously on Day 1 of every 21-day cycle, alongside platinum-based doublet chemotherapy carboplatin or cisplatin for up to four cycles. After chemotherapy, patients continue with maintenance monotherapy of their assigned immunotherapy rilvegostomig or pembrolizumab plus pemetrexed given intravenously on Day 1 of each 21-day cycle. This treatment continues until disease progression or unacceptable toxicity. Throughout the study, participants undergo regular assessments including tumor measurements by CT or MRI scans, organ and bone marrow function tests, and monitoring for side effects. Researchers will measure overall survival and progression-free survival for up to approximately six years. Patient-reported outcomes on physical functioning, quality of life, and lung cancer symptoms are also collected. Safety and pharmacokinetics of rilvegostomig are monitored to understand treatment effects and tolerability over the long term.
Actively Recruiting
Researchers are evaluating the efficacy and safety of elecoglipron for weight management in adults living with obesity or overweight. This Phase III global study includes two independent, randomized, double-blind, placebo-controlled pivotal studies. Study 1 involves adults without type 2 diabetes mellitus T2DM, while Study 2 includes adults with T2DM. Participants have obesity or overweight with at least one weight-related comorbidity such as hypertension, prediabetes, dyslipidemia, cardiovascular disease, or obstructive sleep apnea. Participants will be randomly assigned to receive one of two doses of elecoglipron or a placebo once daily as oral tablets. The treatment lasts 72 weeks, and the study is conducted in multiple centers worldwide. The primary measure is the percentage change in body weight from baseline at 72 weeks. Secondary measures include absolute weight loss, achievement of specific weight loss percentages, waist circumference reduction, glycemic control, and systolic blood pressure reduction. Throughout the study, participants will undergo regular assessments including body weight and waist measurements, laboratory tests related to glycemic control, and blood pressure monitoring. Researchers will also track the achievement of normoglycemia and glycemic control in participants with elevated HbA1c levels. Safety and efficacy data will be collected until the study completion in 2029, with participants monitored closely during the 72-week treatment period.
Actively Recruiting
Researchers are conducting a Phase 1 study to evaluate BHV-1530 alone and in combination with cemiplimab in adults with advanced or metastatic solid tumors. This first-in-human, open-label trial aims to determine the safety, dosing, and potential benefits of BHV-1530 for patients whose cancer has progressed after standard treatments or who have no other available therapies. The study focuses on specific cancers including urothelial cancer, non-small cell lung cancer, and head and neck squamous cell carcinoma, especially those with certain genetic alterations. Participants will receive BHV-1530 as an intravenous infusion on Day 1 of each 21-day cycle, either alone or combined with cemiplimab given on the same schedule. The study includes dose escalation, expansion, and optimization phases to find the maximum tolerable dose and recommended dose range. Some groups may receive the drug alone, while others receive it combined with cemiplimab, with treatment continuing over multiple cycles as determined by the study protocol. During the trial, participants will have regular assessments to monitor safety and treatment effects, including tumor measurements according to RECIST 1.1 criteria and performance status evaluations. Researchers will collect tumor tissue samples, perform laboratory tests, and monitor drug levels in the blood. The main outcomes include determining optimal dosing, safety profile, and clinical benefit rates over an estimated 48 months. Participants health and response to treatment will be carefully followed throughout the study period.
1-10 of 116
1